Standard Biotools Stock Today
| LAB Stock | USD 1.11 0.08 6.72% |
PerformanceWeakest
| Odds Of DistressSmall
|
Standard Biotools is trading at 1.11 as of the 12th of February 2026, a 6.72 percent decrease since the beginning of the trading day. The stock's open price was 1.19. Standard Biotools has about a 32 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of November 2025 and ending today, the 12th of February 2026. Click here to learn more.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. The company has 384.57 M outstanding shares of which 9.79 M shares are now shorted by investors with about 6.63 days to cover. More on Standard Biotools
Standard Stock Highlights
| CEO President | Michael Egholm |
| Old Names | [Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings, Laboratory Corporation of America Holdings, Labo Print SA] |
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Diagnostics & Research, Healthcare (View all Sectors) |
| Financial Strength | |
Standard Biotools (LAB) is traded on NASDAQ Exchange in USA and employs 814 people. Standard Biotools is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 476.86 M. Standard Biotools runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 384.57 M outstanding shares of which 9.79 M shares are now shorted by investors with about 6.63 days to cover.
Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Standard Biotools Probability Of Bankruptcy
Ownership AllocationStandard Biotools shows a total of 384.57 Million outstanding shares. The majority of Standard Biotools outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Standard Biotools to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Standard Biotools. Please pay attention to any change in the institutional holdings of Standard Biotools as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Standard Ownership Details
Standard Biotools Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Standard Biotools market risk premium is the additional return an investor will receive from holding Standard Biotools long position in a well-diversified portfolio.
| Mean Deviation | 3.13 | |||
| Standard Deviation | 4.56 | |||
| Variance | 20.81 | |||
| Risk Adjusted Performance | (0.01) |
Standard Stock Against Markets
Standard Biotools Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Shane Bowen | Chief Officer | Profile | |
| Elizabeth Jensen | Chief Officer | Profile | |
| Mark Spearman | Sr Communications | Profile | |
| Mike Musgnug | Senior Officer | Profile | |
| John Graziano | Vice Relations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. Expected growth trajectory for Standard significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Standard Biotools assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Standard Biotools' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Standard Biotools represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Standard Biotools' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.